These results, coupled with further data showing that the cholesterol-based amphiphilic dendrons were endowed with significantly lower toxic effects than C22G1 in a wide range of concentrations when assayed in a human hepatoblastoma cell line, make the CholSG1 the new lead compound for further translation study as a potential clinical protamine replacer.